trial summary · NCT07594067
TCR1188-ABC Cells in KRAS-mutated Cancers
Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Cholangiocarcinoma, sponsored by University of Pennsylvania. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Source record: https://clinicaltrials.gov/study/NCT07594067
Facts
| registry id | NCT07594067 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Cholangiocarcinoma |
| sponsor | University of Pennsylvania |
| sponsor class | OTHER |
| enrollment | 30 |
| start date | 2026-12 |
| primary completion | 2042-11 |
| completion | 2042-11 |
| results posted | not reported |
Conditions
- Cholangiocarcinoma
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Adenocarcinoma
Interventions
- TCR1188-ABC cells
- Fludarabine + Cyclophosphamide combination
- Tocilizumab
Countries
- United States
Intervention types: BIOLOGICAL, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.